Interactions between ramelteon and Albenza (albendazole)
albendazole and ramelteon (Moderate Drug-Drug)
MONITOR: Coadministration with inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes. In healthy volunteers, pretreatment with the potent CYP450 inducer rifampin (600 mg orally once daily for 11 days) resulted in a mean decrease of approximately 80% (range 40% to 90%) in total systemic exposure (AUC) to ramelteon (32 mg single oral dose) and its pharmacologically active metabolite. Use with other inducers has not been adequately studied.
MANAGEMENT: The efficacy of ramelteon may be reduced when prescribed in combination with potent inducers of CYP450 isoenzymes.
